{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:51:36Z","timestamp":1789771896343,"version":"4.0.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) are widely heterogeneous in their biological behavior, and predicting prognosis and optimal treatment strategies can be challenging.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE PET\/CT is a sensitive imaging modality for well-differentiated NEN and indicates a favorable prognosis, whereas\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT avidity indicates disease that is potentially more aggressive. There has been emerging interest in the combined interpretation of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET and its prognostic significance. We aimed to assess the prognostic utility of a classification system that incorporates the complex findings of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET interpreted side-by-side in patients with metastatic GEP NEN.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We defined 3\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE\/\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG \u201cdual-tracer PET\u201d groups: D1 (\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE positive\/\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG negative), D2 (\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE positive\/\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG positive), and D3 (\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE negative\/\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG positive). We retrospectively assessed the association between the dual-tracer PET classification and progression-free and overall survival (OS) using Kaplan-Meier analysis. Univariate and multivariate analyses were performed using the Cox proportional hazards model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty-seven patients with metastatic GEP NEN and contemporaneous\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET were included. The dual-tracer PET classification was an independent predictor of OS (multivariate\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.016) and also predicted progression-free survival (univariate\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.030). Other independent predictors of OS included chromogranin A and World Health Organization (WHO) grade. WHO grade was not associated with OS from the time of dual-tracer PET but was an independent predictor of OS from the date of histological diagnosis (multivariate\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our study demonstrates that a classification system combining the complex findings of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET is correlated with prognosis. Further research is needed to prospectively validate these findings and to explore whether dual-tracer PET scores may also be able to predict response to treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003937","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T12:08:09Z","timestamp":1638878889000},"page":"26-35","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":32,"title":["The Combined Interpretation of 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors"],"prefix":"10.1097","volume":"47","author":[{"given":"Aimee R.","family":"Hayes","sequence":"first","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Furtado O'Mahony","sequence":"additional","affiliation":[{"name":"Medical School, University College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Gnanasegaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn E.","family":"Caplin","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunak","family":"Navalkissoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","year":"2017","journal-title":"JAMA Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1309\/AJCPQ55SKOCYFZHN","article-title":"Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and world health organization grade discordance with primary tumors","volume":"143","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/PAS.0b013e31821a0696","article-title":"Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification","volume":"35","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological, nuclear medicine and hybrid imaging","volume":"105","year":"2017","journal-title":"Neuroendocrinology"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1007\/s00259-014-2850-3","article-title":"Comparison of the prognostic values of 68Ga-DOTANOC PET\/CT and 18F-FDG PET\/CT in patients with well-differentiated neuroendocrine tumor","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2217\/fon-2017-0393","article-title":"The utility of 68Ga-DOTATATE positron-emission tomography\/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors","volume":"14","year":"2018","journal-title":"Future Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.114.144386","article-title":"High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation","volume":"55","year":"2014","journal-title":"J Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","year":"2010","journal-title":"Clin Cancer Res"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2967\/jnumed.120.244798","article-title":"18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/jcm8071032","article-title":"Role of combined [68Ga]Ga-DOTA-SST analogues and [18F]FDG PET\/CT in the management of GEP-NENs: a systematic review","volume":"8","year":"2019","journal-title":"J Clin Med"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1\u2014update and clarification: from the RECIST committee","volume":"62","year":"2016","journal-title":"Eur J Cancer"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance","volume":"7","year":"2017","journal-title":"Theranostics"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"589","DOI":"10.18632\/oncotarget.27460","article-title":"Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias","volume":"11","year":"2020","journal-title":"Oncotarget"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.cgh.2008.02.052","article-title":"Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors","volume":"6","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1210\/jc.2011-0666","article-title":"Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus","volume":"96","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1159\/000504392","article-title":"High-grade progression confers poor survival in pancreatic neuroendocrine tumors","volume":"110","year":"2020","journal-title":"Neuroendocrinology"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1200\/JCO.19.00980","article-title":"Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the Getne-Trasgu study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2967\/jnumed.118.224386","article-title":"Parameters to predict progression-free and overall survival after peptide receptor radionuclide therapy: a multivariate analysis in 782 patients","volume":"60","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T16:06:33Z","timestamp":1750521993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003937"}},"subtitle":["A Classification System With Prognostic Impact"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003937","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}